ArticleDigestive diseases and sciences1999
Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy.
Article in Digestive diseases and sciences, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01430039 (Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease
Who cites it
20 citing papers in PubMed, 64 citations in OpenAlex.
- Inflammatory bowel disease and extracellular matrix: when victim becomes double agent.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- The Mechanism and Potential Therapeutic Effects of Cyclosporin, Cyclophilin, Probiotics and Syndecan-1 in an Animal Model of Inflammatory Bowel Disease.Pharmaceutics · 2024Article
- Article
- Review
- Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma.PloS one · 2017Article
- Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2015Article
- Serum Syndecan-1 Levels and Its Relationship to Disease Activity in Patients with Crohn's Disease.Gastroenterology research and practice · 2015Article
- Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory Responses.PloS one · 2015Article
- Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin?World journal of gastrointestinal pathophysiology · 2013Review
- Altered molecular pattern of mucosal healing in Crohn's disease fibrotic stenosis.World journal of gastrointestinal pathophysiology · 2013Article
- Heparan sulfate on intestinal epithelial cells plays a critical role in intestinal crypt homeostasis via Wnt/β-catenin signaling.American journal of physiology. Gastrointestinal and liver physiology · 2013Article
- Versatile role of heparanase in inflammation.Matrix biology : journal of the International Society for Matrix Biology · 2013Review
- Heparanase in inflammation and inflammation-associated cancer.The FEBS journal · 2013Review
- Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.Cellular and molecular life sciences : CMLS · 2012Review
- Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.The American journal of pathology · 2010Article
- The microvascular thrombi of colonic tissue in ulcerative colitis.Digestive diseases and sciences · 2007Article
- Heparan sulfate proteoglycans mediate Staphylococcus aureus interactions with intestinal epithelium.Medical microbiology and immunology · 2006Article
- Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes.World journal of gastroenterology · 2004Article
- Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.Digestive diseases and sciences · 2001Article
- Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation.The American journal of pathology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin apparently aids healing in ulcerative colitis although its mechanism of action is unknown. The purpose of this study was to investigate the hypothesis that heparin functions as a coreceptor molecule for basic fibroblast growth factor, a role usually performed by heparan sulfate chains on syndecan-1. A marked reduction of syndecan-1 immunostaining was found in reparative epithelium from inflammatory bowel disease patients. Removal of heparan sulfate on gastrointestinal epithelial cells in vitro reduced the proliferative response to basic fibroblast growth factor. The response to basic fibroblast growth factor was completely restored by the addition of heparin. Loss of syndecan-1 expression occurs in the regenerative mucosa in inflammatory bowel disease. Although this may facilitate tissue motility, its loss probably adversely affects the ability of cells to bind basic fibroblast growth factor. The present data show that heparin may substitute the loss of functional activity of syndecan-1 in the binding of basic fibroblast growth factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.